Core Points - Cidara Therapeutics (CDTX.US) shares surged over 105% to a new eight-year high of $217.8 following the announcement of a definitive agreement for acquisition by Merck (MRK.US) at $221.50 per share in cash [1] - The total value of the transaction is approximately $9.2 billion, and it has been approved by the boards of both companies [1] - The acquisition is subject to the approval of the Hart-Scott-Rodino Antitrust Improvements Act (HSR) and other customary closing conditions, with an expected completion in the first quarter of 2026 [1] - Merck's research laboratories president, Dr. D. Lee, stated that this acquisition expands and enhances their respiratory product portfolio and R&D pipeline [1]

周五，Cidara Therapeutics(CDTX.US)开盘飙升超105%，创八年新高，报217.8美元。消息面上，默沙东 (MRK.US)宣布已达成最终协议，将通过其子公司以每股221.50美元的现金收购Cidara Therapeutics，交 易总价值约为92亿美元，后者是一家首创长效流感抗体的制药商。该交易已获得双方董事会批准，但仍 需获得《哈特-斯科特-罗迪诺反垄断改进法案》(HSR)的批准以及其他惯例成交条件。该交易预计将于 2026年第一季度完成。默沙东研究实验室总裁李迪安博士表示，此次收购扩大并完善了我们的呼吸系统 产品组合和研发管线。 ...